Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
The Evidence Forum

The spring issue of The Evidence Forum is out

Learn more about evidence needs for rare disease treatments

Read Now
Latest News

For the second year in a row, PPD has been named to Forbes magazine’s 2019 list of America’s Best Large Employers

Read More
Featured Articles

Read Evidera’s featured articles in pharmaphorum Deep Dive: Disruptive Technologies

Discover our experts’ take on disruptive technologies in “Machine learning: Opening doors in pharmaceutical development“ and “Data disruption and applying ‘enabled intelligence’”

Read Now
White Paper

How social media can be used to understand what matters to people with rare diseases

Discover how social media offers a wealth of information on patient insight into rare diseases

Read Now
Latest News

Collaboration with China-based HLT creates opportunity to expand access to real-world data and patients in China

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2017 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Gastroenterology

Moderately Severe and Severe Acute Pancreatitis : A Systematic Review of the Outcomes in the USA and European Union-5

  • BMJ Open Gastroenterology
  • April 2019
Endocrinology

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

  • Diabetes Therapy
  • April 2019
Oncology

Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML)

  • Journal of Medical Economics
  • March 2019
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.
Anuraag Kansal, PhD, Sr. Research Leader & Director, Disease & Trial Simulation, Modeling & Simulation at Evidera

In Our Own Words

Our work simulating Alzheimer’s disease progression allows us to offer clients insight into their trial designs, simulate outcomes of alternative designs, and enable clients to anticipate results and make decisions accordingly.

CUP Case Study
Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.

Read More
Case Study

Compassionate Use Program: Rapid Drug Delivery to Patients in Need

Learn how Evidera, as part of PPD, created a global program across 38 countries to provide treatment within 24-48 hours to 3,100 patients.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More